Boc-NH-cis-cyclooctane-COOH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Boc-NH-cis-cyclooctane-COOH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
BOC-Amino Acids
Catalog number
BAT-005245
CAS number
1013980-15-8
Molecular Formula
C14H25NO4
Molecular Weight
271.35
Boc-NH-cis-cyclooctane-COOH
IUPAC Name
(1S,2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclooctane-1-carboxylic acid
Synonyms
(1S,2R/1R,2S)-2-[(tert-butoxycarbonyl)amino]cyclooctanecarboxylic acid; cis-2-Tert-butoxycarbonylamino-cyclooctanecarboxylic acid
Purity
95%
InChI
InChI=1S/C14H25NO4/c1-14(2,3)19-13(18)15-11-9-7-5-4-6-8-10(11)12(16)17/h10-11H,4-9H2,1-3H3,(H,15,18)(H,16,17)/t10-,11+/m1/s1
InChI Key
XCJDZYKLPCSUNZ-MNOVXSKESA-N
Canonical SMILES
CC(C)(C)OC(=O)NC1CCCCCCC1C(=O)O
1.(-)-Hydroxycitric Acid Nourishes Protein Synthesis via Altering Metabolic Directions of Amino Acids in Male Rats.
Han N1, Li L1, Peng M1, Ma H1. Phytother Res. 2016 May 4. doi: 10.1002/ptr.5630. [Epub ahead of print]
(-)-Hydroxycitric acid (HCA), a major active ingredient of Garcinia Cambogia extracts, had shown to suppress body weight gain and fat accumulation in animals and humans. While, the underlying mechanism of (-)-HCA has not fully understood. Thus, this study was aimed to investigate the effects of long-term supplement with (-)-HCA on body weight gain and variances of amino acid content in rats. Results showed that (-)-HCA treatment reduced body weight gain and increased feed conversion ratio in rats. The content of hepatic glycogen, muscle glycogen, and serum T4 , T3 , insulin, and Leptin were increased in (-)-HCA treatment groups. Protein content in liver and muscle were significantly increased in (-)-HCA treatment groups. Amino acid profile analysis indicated that most of amino acid contents in serum and liver, especially aromatic amino acid and branched amino acid, were higher in (-)-HCA treatment groups. However, most of the amino acid contents in muscle, especially aromatic amino acid and branched amino acid, were reduced in (-)-HCA treatment groups.
2.Uncovering the Evolution of Lead In-Use Stocks in Lead-Acid Batteries and the Impact on Future Lead Metabolism in China.
Liu W1, Chen L1,2, Tian J1. Environ Sci Technol. 2016 May 4. [Epub ahead of print]
This study aims to illustrate the evolution of lead in-use stocks, particularly in lead-acid batteries (LABs), and their impact on future lead metabolism in China. First, we used a bottom-up methodology to study the evolution of lead in-use stocks in China from 2000 to 2014. It was found that the lead in-use stocks increased from 0.91 to 7.75 Mt. The principal driving force of such change is the rapid development of LABs-driven electric vehicles. Then, we proposed three scenarios, low, baseline, and high in-use stocks, to project the lead demand and supply toward 2030. The results show that the LAB demand will decrease as a result of competition and replacement by lithium ion batteries. The lead demand in China will come to a peak around 2018-2020 under the three scenarios, then reduce to 3.7, 4.6, and 5.3 Mt/yr in 2030. Meanwhile, primary lead outputs will follow the increase of zinc production in China. Secondary lead recovered from spent LABs will also increase gradually.
Online Inquiry
Verification code
Inquiry Basket